Q32 Bio Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update on its bempikibart development program. The company announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial, showing a mean SALT score reduction of 35.3% and a 40.0% SALT-20 response rate in the mITT population. Q32 Bio completed a $200 million public offering in July 2026, bringing total cash resources to approximately $306.3 million as it prepares for a registration-directed program expected to initiate in the first half of 2027. For the quarter, the company reported a net loss of $8.9 million, or $0.44 per share, with research and development expenses at $4.3 million. Q32 Bio is a clinical-stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases.

Q32 Bio Inc. entered into an underwriting agreement on July 14, 2026, to issue and sell 6,027,399 shares of common stock at $18.25 per share and 4,931,506 pre-funded warrants at $18.2499 per warrant. The offering is expected to close on July 16, 2026, with estimated net proceeds of approximately $187.6 million, potentially increasing to $215.8 million if underwriters exercise their option to purchase additional shares. The company intends to use the proceeds for working capital and to support the advancement of bempikibart into future clinical trials. Q32 Bio Inc. is a biotechnology company focused on developing clinical-stage drug candidates.

Q32 Bio Inc. announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata. The company used a presentation to communicate these findings. Q32 Bio Inc. is a biotechnology company focused on developing medical treatments for autoimmune diseases.

Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in patients with alopecia areata, showing a 35.3% mean reduction in SALT scores. The company also reported that it paid off the remaining $6.8 million balance of its loan with Silicon Valley Bank on June 24, 2026. Q32 Bio Inc. is a biotechnology company focused on developing therapeutic candidates for autoimmune diseases.